JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033. Click here to read why JNJ is a Hold.
Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback